Sarah Owen

Sarah is a Principal Scientist at Pfizer and a member of the Bioassay team within Analytical Research & Development (ARD). She leads assay development for fit for purpose characterization and release methods, with a primary focus on antibody drug conjugates (ADCs). Her expertise includes both binding and cell based assays. She leads the Effector Function sub team and supports a unified effector function strategy across the ADC portfolio. In this role, she oversees development of phase appropriate methods for effector function characterization and comparability, where applicable. A key focus of her work is the development of adaptable platform methods that enable rapid application across programs to deliver timely results. Sarah also serves as a bioassay lead on multiple programs, overseeing method development, qualification, and transfer for both early and late phase programs. Prior to joining Pfizer, she earned her Ph.D. in Chemical Engineering from the University of Michigan, where her research focused on developing analytical tools to isolate and characterize circulating cancer biomarkers from blood.